Respiratory virus vaccination season begins in North America

The respiratory virus vaccination season has commenced, with health authorities emphasizing protection against influenza, COVID-19, and, for certain groups, respiratory syncytial virus (RSV).

In the United States, Moderna has introduced mFLUSIVA, an mRNA-based flu vaccine. Studies suggest it may offer 27% more protection than traditional vaccines for certain age groups. While it is egg-free, it may cause slightly more side effects, such as headaches or fatigue. Currently, mFLUSIVA is primarily available through Walgreens pharmacies.

In Canada, specifically Quebec, health officials are targeting a vaccination rate of at least 80% among high-risk populations. Free vaccinations for influenza and COVID-19 are recommended for seniors aged 65 and older, pregnant women, and individuals with chronic conditions such as diabetes, heart disease, or respiratory issues. These measures aim to reduce hospitalizations and mortality rates.